AU2018305209B2 - Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody - Google Patents

Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody

Info

Publication number
AU2018305209B2
AU2018305209B2 AU2018305209A AU2018305209A AU2018305209B2 AU 2018305209 B2 AU2018305209 B2 AU 2018305209B2 AU 2018305209 A AU2018305209 A AU 2018305209A AU 2018305209 A AU2018305209 A AU 2018305209A AU 2018305209 B2 AU2018305209 B2 AU 2018305209B2
Authority
AU
Australia
Prior art keywords
seq
cdr
antibody
nos
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018305209A
Other languages
English (en)
Other versions
AU2018305209A1 (en
Inventor
Aymen Al-Shamkhani
Stephen Beers
Björn FRENDÉUS
Martin Glennie
Juliet GRAY
Linda MÅRTENSSON
Monika SEMMRICH
Ingrid Teige
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Bioinvent International AB
Original Assignee
Cancer Research Technology Ltd
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, Bioinvent International AB filed Critical Cancer Research Technology Ltd
Publication of AU2018305209A1 publication Critical patent/AU2018305209A1/en
Application granted granted Critical
Publication of AU2018305209B2 publication Critical patent/AU2018305209B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018305209A 2017-07-26 2018-07-26 Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody Active AU2018305209B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1712032.0A GB201712032D0 (en) 2017-07-26 2017-07-26 Antibodies and uses thereof
GB1712032.0 2017-07-26
PCT/EP2018/070359 WO2019020774A2 (en) 2017-07-26 2018-07-26 NOVEL ANTIBODIES AND COMBINED USE OF ANTIBODY THAT INDUCES TREG DEPLOYMENT AND AN IMMUNOSTIMULATOR ANTIBODY

Publications (2)

Publication Number Publication Date
AU2018305209A1 AU2018305209A1 (en) 2020-02-06
AU2018305209B2 true AU2018305209B2 (en) 2025-06-26

Family

ID=59771732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018305209A Active AU2018305209B2 (en) 2017-07-26 2018-07-26 Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody

Country Status (8)

Country Link
US (2) US11447549B2 (enExample)
EP (1) EP3658587A2 (enExample)
JP (3) JP7458973B2 (enExample)
CN (1) CN111108124B (enExample)
AU (1) AU2018305209B2 (enExample)
CA (1) CA3070290A1 (enExample)
GB (1) GB201712032D0 (enExample)
WO (1) WO2019020774A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020204A1 (en) * 2016-04-07 2017-10-12 Cancer Research Technology Limited Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
ES2903440T3 (es) * 2018-09-13 2022-04-01 Euroimmun Medizinische Labordiagnostika Ag Procedimiento y dispositivo para registrar y visualizar una imagen de inmunofluorescencia de una muestra biológica
JP2022530026A (ja) 2019-04-24 2022-06-27 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマトキシン抗体薬物複合体及びその使用
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016200835A1 (en) * 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
WO2017077085A2 (en) * 2015-11-04 2017-05-11 Cancer Research Technology Immunomodulatory antibodies
WO2017174331A1 (en) * 2016-04-07 2017-10-12 Cancer Research Technology Limited Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107172880B (zh) * 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
WO2015188047A1 (en) * 2014-06-06 2015-12-10 University Of Maryland, Baltimore ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
CN110256558B (zh) 2014-12-23 2023-07-04 百时美施贵宝公司 针对tigit的抗体
AU2016235362B2 (en) 2015-03-23 2021-12-16 Jounce Therapeutics, Inc. Antibodies to ICOS
WO2018225035A1 (en) * 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016200835A1 (en) * 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
WO2017077085A2 (en) * 2015-11-04 2017-05-11 Cancer Research Technology Immunomodulatory antibodies
WO2017174331A1 (en) * 2016-04-07 2017-10-12 Cancer Research Technology Limited Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Arce Vargas, F. et al., 'Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors', Immunity, (2017-04-01), vol. 46, no. 4, pages 577 - 586. *
Franklin, C. et al., 'Immunotherapy in melanoma: Recent Advances and future directions' EJSO, (2016-09-02); vol. 43, no. 3, pages 604-411, doi: 10.1016/J.EJS0.2016.07.145. *
Guo, Z. et al., 'PD-1 blockade and OX40 triggering synergyistically protects against tumor growth in a murine model of ovarian cancer, PLoS One, (2014-02-27), vol. 9, no. 2, e89350, doi:10.1371/journal.pone.0089350 *
Houot, R. et al., 'Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion', Blood, (2009-10-15), vol. 114, no. 16, pages 3431 - 3438, doi: 10.1182/blood-2009-05-223958. *
Linch, S. et al., 'OX40 agonists and combination immunotherapy: Putting the pedal to the metal', Frontiers in Oncology, Frontiers Research Foundation, (2015-02-16), vol. 5, no. 16, pages 1 - 14, doi:10.3389/FONC.2015.00034 *
Mahoney, K. et al., 'Combination cancer immunotherapy and new immunomodulatory targets', Nature Reviews Drug Discovery, (2015-07-03), vol. 14, no. 8, pages 561-584, doi: 10.1038/nrd4591. *
Piconese, S. et al., 'OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection', The Journal of Experimental Medicines, (2008-04-01), vol. 205, no. 4, pages 825 - 839, doi: 10.1084/JEM.2007134. *
Simpson, T. et al., ;Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma'. J Exp Med, (2013), vol. 210, no. 9, pages 1695-1710, doi: 10.1084/jem.20130579. *
Wolchok, J. et al., 'Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients', N Engl J Med, (2013-07-11), vol. 369, no. 2, pages 1-19, doi:10.1056/NEJMoa1302369. *
Yonezawa, A. et al., 'Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy', Clinical Cancer Research, (2015-04-23), vol. 21, pages 3113 - 3120, doi: 10.1158/1078-0432.CCR-15-0263. *

Also Published As

Publication number Publication date
CA3070290A1 (en) 2019-01-31
GB201712032D0 (en) 2017-09-06
JP2025157343A (ja) 2025-10-15
JP2023129433A (ja) 2023-09-14
JP2020528765A (ja) 2020-10-01
WO2019020774A2 (en) 2019-01-31
US20230058227A1 (en) 2023-02-23
US20200207855A1 (en) 2020-07-02
AU2018305209A1 (en) 2020-02-06
EP3658587A2 (en) 2020-06-03
WO2019020774A3 (en) 2019-05-02
CN111108124A (zh) 2020-05-05
US11447549B2 (en) 2022-09-20
CN111108124B (zh) 2024-09-03
JP7458973B2 (ja) 2024-04-01

Similar Documents

Publication Publication Date Title
AU2018305209B2 (en) Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody
AU2018233976B2 (en) Fc-optimized anti-CD25 for tumour specific cell depletion
AU2017247880B2 (en) Anti CD25 FC gamma receptor bispecific antibodies for tumor specific cell depletion
WO2022003156A1 (en) Ccr8 non-blocking binders
AU2019207767B2 (en) Novel combination and use of antibodies
WO2019008386A1 (en) COMPOUNDS AND METHODS FOR DEPLOYING SPECIFIC CELLS FROM A TUMOR
KR20200140315A (ko) 항-cd27 항체 및 그의 용도
CN113840839B (zh) 人源化和亲和力成熟的抗ceacam1抗体
EP3617230A1 (en) Novel antibodies and nucleotide sequences, and uses thereof
RU2816531C2 (ru) Комбинации антител для лечения рака у конкретных пациентов
RU2800035C2 (ru) Новая комбинация антител и ее применение
RU2839380C1 (ru) Fc-оптимизированные антитела к cd25 для истощения опухолеспецифических клеток
CA3210609A1 (en) Novel combinations of antibodies and uses thereof
HK40016585B (zh) 用於肿瘤特异性细胞消耗的fc优化的抗cd25
HK1262659A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
HK40016585A (en) Fc-optimized anti-cd25 for tumor specific cell depletion

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)